Figure 2 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma

Response of parental, AfaR, and ErlR models to AURKAi monotherapy. A, Representative Western blot images showing baseline activation and total levels of AURKA. B, Quantification of immunoprecipitation assay probing for phospho-AURKA (T288) and total AURKA protein levels. C, Representative Western blot images of TPX2 and NEDD9. D, Western blot quantification for baseline levels of TPX2 and NEDD9, with antibodies to total protein. E, Dose–response curves for parental, ErlR, and AfaR cell models treated with the indicated dose range of VIC-1911 for 72 hours. F, Fadu/Cal27 parental and derived resistant models were treated with vehicle and VIC-1911 (0.6 μmol/L) for 24 hours. Protein level quantification for phospho-EGFR (y1068) was relative to total EGFR, phospho-AKT (S473) relative to total AKT, phospho-ERK (Y204) relative to total ERK, total AURKA, TPX2, and BimEL relative to the loading control. Bar graphs display data normalized to each parental cell line. All graphs were quantified from at least three independent biological repeats. P values are based on one-way ANOVA followed by Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.